COVIVIO (COV.PA) Stock Fundamental Analysis

Europe • Euronext Paris • EPA:COV • FR0000064578

53.6 EUR
-0.15 (-0.28%)
Last: Feb 2, 2026, 07:00 PM
Fundamental Rating

4

Taking everything into account, COV scores 4 out of 10 in our fundamental rating. COV was compared to 42 industry peers in the Diversified REITs industry. COV has a medium profitability rating, but doesn't score so well on its financial health evaluation. COV has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year COV was profitable.
  • In the past year COV had a positive cash flow from operations.
  • Of the past 5 years COV 4 years were profitable.
  • In the past 5 years COV always reported a positive cash flow from operatings.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B -1B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 1.63%, COV is in line with its industry, outperforming 47.62% of the companies in the same industry.
  • COV has a Return On Equity (5.08%) which is in line with its industry peers.
  • Looking at the Return On Invested Capital, with a value of 3.21%, COV is in line with its industry, outperforming 50.00% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for COV is in line with the industry average of 3.37%.
  • The last Return On Invested Capital (3.21%) for COV is above the 3 year average (2.97%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROIC 3.21%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

  • COV's Profit Margin of 30.43% is in line compared to the rest of the industry. COV outperforms 47.62% of its industry peers.
  • In the last couple of years the Profit Margin of COV has declined.
  • COV has a worse Operating Margin (57.80%) than 61.90% of its industry peers.
  • COV's Operating Margin has been stable in the last couple of years.
  • The Gross Margin of COV (74.42%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of COV has remained more or less at the same level.
Industry RankSector Rank
OM 57.8%
PM (TTM) 30.43%
GM 74.42%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

1

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so COV is destroying value.
  • COV has more shares outstanding than it did 1 year ago.
  • COV has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for COV has been reduced compared to a year ago.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

  • Based on the Altman-Z score of 0.53, we must say that COV is in the distress zone and has some risk of bankruptcy.
  • COV's Altman-Z score of 0.53 is on the low side compared to the rest of the industry. COV is outperformed by 71.43% of its industry peers.
  • COV has a debt to FCF ratio of 28.49. This is a negative value and a sign of low solvency as COV would need 28.49 years to pay back of all of its debts.
  • COV's Debt to FCF ratio of 28.49 is on the low side compared to the rest of the industry. COV is outperformed by 69.05% of its industry peers.
  • COV has a Debt/Equity ratio of 1.07. This is a high value indicating a heavy dependency on external financing.
  • COV's Debt to Equity ratio of 1.07 is on the low side compared to the rest of the industry. COV is outperformed by 76.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.49
Altman-Z 0.53
ROIC/WACC0.55
WACC5.8%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

  • A Current Ratio of 0.76 indicates that COV may have some problems paying its short term obligations.
  • COV's Current ratio of 0.76 is fine compared to the rest of the industry. COV outperforms 69.05% of its industry peers.
  • COV has a Quick Ratio of 0.76. This is a bad value and indicates that COV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • COV has a Quick ratio of 0.69. This is in the better half of the industry: COV outperforms 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.69
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

5

3. Growth

3.1 Past

  • The Earnings Per Share has been growing slightly by 5.98% over the past year.
  • COV shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -3.39% yearly.
  • COV shows a strong growth in Revenue. In the last year, the Revenue has grown by 27.96%.
  • The Revenue has been growing slightly by 1.17% on average over the past years.
EPS 1Y (TTM)5.98%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%6.25%
Revenue 1Y (TTM)27.96%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.61%

3.2 Future

  • COV is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.53% yearly.
  • COV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.10% yearly.
EPS Next Y5.02%
EPS Next 2Y3.41%
EPS Next 3Y3.53%
EPS Next 5YN/A
Revenue Next Year1.77%
Revenue Next 2Y3.17%
Revenue Next 3Y4.1%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 11.63 indicates a reasonable valuation of COV.
  • Based on the Price/Earnings ratio, COV is valued a bit cheaper than 69.05% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of COV to the average of the S&P500 Index (28.41), we can say COV is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 11.21, the valuation of COV can be described as reasonable.
  • Based on the Price/Forward Earnings ratio, COV is valued a bit cheaper than 61.90% of the companies in the same industry.
  • COV is valuated cheaply when we compare the Price/Forward Earnings ratio to 25.64, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 11.63
Fwd PE 11.21
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 66.67% of the companies in the same industry are more expensive than COV, based on the Enterprise Value to EBITDA ratio.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as COV.
Industry RankSector Rank
P/FCF 15.24
EV/EBITDA 16.77
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PEG (NY)2.32
PEG (5Y)N/A
EPS Next 2Y3.41%
EPS Next 3Y3.53%

More info and screens

4

5. Dividend

5.1 Amount

  • COV has a Yearly Dividend Yield of 6.49%, which is a nice return.
  • COV's Dividend Yield is a higher than the industry average which is at 5.30.
  • Compared to an average S&P500 Dividend Yield of 1.83, COV pays a better dividend.
Industry RankSector Rank
Dividend Yield 6.49%

5.2 History

  • The dividend of COV decreases each year by -1.54%.
Dividend Growth(5Y)-1.54%
Div Incr Years2
Div Non Decr Years2
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

  • COV pays out 92.86% of its income as dividend. This is not a sustainable payout ratio.
DP92.86%
EPS Next 2Y3.41%
EPS Next 3Y3.53%
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

More info and screens

COVIVIO

EPA:COV (2/2/2026, 7:00:00 PM)

53.6

-0.15 (-0.28%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)N/A
Earnings (Next)02-18
Inst Owners42.11%
Inst Owner ChangeN/A
Ins Owners0.27%
Ins Owner ChangeN/A
Market Cap5.98B
Revenue(TTM)1.37B
Net Income(TTM)417.40M
Analysts80
Price Target63.23 (17.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.49%
Yearly Dividend0.72
Dividend Growth(5Y)-1.54%
DP92.86%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.29%
PT rev (3m)-1.87%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.04%
EPS NY rev (3m)-0.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.05%
Valuation
Industry RankSector Rank
PE 11.63
Fwd PE 11.21
P/S 4.36
P/FCF 15.24
P/OCF 5.96
P/B 0.73
P/tB 0.76
EV/EBITDA 16.77
EPS(TTM)4.61
EY8.6%
EPS(NY)4.78
Fwd EY8.92%
FCF(TTM)3.52
FCFY6.56%
OCF(TTM)8.99
OCFY16.77%
SpS12.29
BVpS73.66
TBVpS70.57
PEG (NY)2.32
PEG (5Y)N/A
Graham Number87.41
Profitability
Industry RankSector Rank
ROA 1.63%
ROE 5.08%
ROCE 3.59%
ROIC 3.21%
ROICexc 3.42%
ROICexgc 3.48%
OM 57.8%
PM (TTM) 30.43%
GM 74.42%
FCFM 28.62%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
ROICexc(3y)3.08%
ROICexc(5y)2.79%
ROICexgc(3y)3.11%
ROICexgc(5y)2.81%
ROCE(3y)3.32%
ROCE(5y)3%
ROICexgc growth 3Y12.16%
ROICexgc growth 5Y0.31%
ROICexc growth 3Y11.77%
ROICexc growth 5Y0.14%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 28.49
Debt/EBITDA 9.39
Cap/Depr 415.79%
Cap/Sales 44.53%
Interest Coverage 250
Cash Conversion 106.78%
Profit Quality 94.06%
Current Ratio 0.76
Quick Ratio 0.69
Altman-Z 0.53
F-Score7
WACC5.8%
ROIC/WACC0.55
Cap/Depr(3y)709.28%
Cap/Depr(5y)708.5%
Cap/Sales(3y)50.08%
Cap/Sales(5y)56.76%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.98%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%6.25%
EPS Next Y5.02%
EPS Next 2Y3.41%
EPS Next 3Y3.53%
EPS Next 5YN/A
Revenue 1Y (TTM)27.96%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.61%
Revenue Next Year1.77%
Revenue Next 2Y3.17%
Revenue Next 3Y4.1%
Revenue Next 5YN/A
EBIT growth 1Y-0.75%
EBIT growth 3Y7.42%
EBIT growth 5Y0.05%
EBIT Next Year12.83%
EBIT Next 3Y8.07%
EBIT Next 5Y7.52%
FCF growth 1Y41.8%
FCF growth 3YN/A
FCF growth 5Y31.13%
OCF growth 1Y30.51%
OCF growth 3Y12.5%
OCF growth 5Y4.86%

COVIVIO / COV.PA FAQ

Can you provide the ChartMill fundamental rating for COVIVIO?

ChartMill assigns a fundamental rating of 4 / 10 to COV.PA.


What is the valuation status for COV stock?

ChartMill assigns a valuation rating of 5 / 10 to COVIVIO (COV.PA). This can be considered as Fairly Valued.


Can you provide the profitability details for COVIVIO?

COVIVIO (COV.PA) has a profitability rating of 4 / 10.


What is the financial health of COVIVIO (COV.PA) stock?

The financial health rating of COVIVIO (COV.PA) is 1 / 10.


How sustainable is the dividend of COVIVIO (COV.PA) stock?

The dividend rating of COVIVIO (COV.PA) is 4 / 10 and the dividend payout ratio is 92.86%.